JOP20170064B1 - أجسام مضادة لـ TNF-a وشظايا وظيفية منها - Google Patents

أجسام مضادة لـ TNF-a وشظايا وظيفية منها

Info

Publication number
JOP20170064B1
JOP20170064B1 JOP/2017/0064A JOP20170064A JOP20170064B1 JO P20170064 B1 JOP20170064 B1 JO P20170064B1 JO P20170064 A JOP20170064 A JO P20170064A JO P20170064 B1 JOP20170064 B1 JO P20170064B1
Authority
JO
Jordan
Prior art keywords
tnfa
functional fragments
antibodies
binding
processes
Prior art date
Application number
JOP/2017/0064A
Other languages
English (en)
Inventor
Gunde Tea
Meyer Sebastian
Maria Furrer Esther
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Application granted granted Critical
Publication of JOP20170064B1 publication Critical patent/JOP20170064B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بجزيئات أجسام مضادة وشظايا وظيفية منها، قادرة على الارتباط بعامل تنكرز الورم ألفا (TNFa)، وبعمليات لإنتاجها واستخدامها علاجيا.andnbsp;
JOP/2017/0064A 2016-03-17 2017-03-16 أجسام مضادة لـ TNF-a وشظايا وظيفية منها JOP20170064B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16160907.8A EP3219726B1 (en) 2016-03-17 2016-03-17 Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number Publication Date
JOP20170064B1 true JOP20170064B1 (ar) 2021-08-17

Family

ID=55542576

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2017/0064A JOP20170064B1 (ar) 2016-03-17 2017-03-16 أجسام مضادة لـ TNF-a وشظايا وظيفية منها
JOP/2021/0085A JOP20210085A1 (ar) 2016-03-17 2021-04-22 أجسام مضادة لـ TNF- alpha وشظايا وظيفية منها

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0085A JOP20210085A1 (ar) 2016-03-17 2021-04-22 أجسام مضادة لـ TNF- alpha وشظايا وظيفية منها

Country Status (39)

Country Link
US (3) US11459383B2 (ar)
EP (3) EP3219726B1 (ar)
JP (2) JP7129398B2 (ar)
KR (2) KR102470235B1 (ar)
CN (1) CN109071650B (ar)
AR (1) AR107917A1 (ar)
AU (1) AU2017235387A1 (ar)
BR (1) BR112018016667A2 (ar)
CA (1) CA3011784C (ar)
CL (1) CL2018002649A1 (ar)
CO (1) CO2018009783A2 (ar)
CR (1) CR20180448A (ar)
CY (1) CY1123784T1 (ar)
DK (2) DK3219726T3 (ar)
EA (1) EA039760B1 (ar)
ES (2) ES2836349T3 (ar)
FI (1) FI3430043T3 (ar)
GE (1) GEP20217307B (ar)
HR (2) HRP20231464T1 (ar)
HU (2) HUE052773T2 (ar)
IL (1) IL261031A (ar)
JO (2) JOP20170064B1 (ar)
LT (2) LT3219726T (ar)
MA (1) MA43717B1 (ar)
MD (1) MD3430043T2 (ar)
MX (1) MX2018011258A (ar)
MY (1) MY194041A (ar)
PH (1) PH12018501907A1 (ar)
PL (2) PL3219726T3 (ar)
PT (2) PT3219726T (ar)
RS (2) RS61374B1 (ar)
SA (1) SA518400027B1 (ar)
SG (1) SG11201807062RA (ar)
SI (2) SI3219726T1 (ar)
TN (1) TN2018000298A1 (ar)
TW (2) TWI829444B (ar)
UY (1) UY37157A (ar)
WO (1) WO2017158092A1 (ar)
ZA (4) ZA202108602B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018017165A2 (pt) 2016-03-17 2019-01-02 Numab Innovation Ag anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos
SI3219726T1 (sl) * 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
RS61412B1 (sr) 2016-03-17 2021-03-31 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
EP3456737B1 (en) * 2017-09-19 2024-02-14 Tillotts Pharma Ag Antibody variants
HUE054261T2 (hu) * 2017-09-19 2021-08-30 Tillotts Pharma Ag Antitest variánsok
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
RU2224766C2 (ru) 1997-04-14 2004-02-27 Микромет Аг Способ получения рецепторов для человеческих антигенов и их применение
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE384792T1 (de) 1998-11-18 2008-02-15 Genentech Inc Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
WO2006131013A2 (en) 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
ES2687259T5 (es) 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
CN102164958A (zh) 2008-06-25 2011-08-24 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 使用通用抗体构架进行的兔抗体的人源化
CN104800147A (zh) 2008-07-10 2015-07-29 德勒尼克斯治疗股份公司 用于大分子的增强的递送的方法和组合物
RU2012147249A (ru) * 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
CN108314733A (zh) * 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
US9096669B2 (en) 2010-09-30 2015-08-04 Chengdu Kanghong Biotechnologies Co., Ltd. Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same
EP3013864A1 (en) 2013-06-26 2016-05-04 Numab AG Novel antibody frameworks
WO2015065987A1 (en) * 2013-11-01 2015-05-07 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
KR20160142849A (ko) * 2014-03-26 2016-12-13 셀 메디카 스위처란트 아게 Tnf 알파에 대한 결합 구성원
RS61412B1 (sr) 2016-03-17 2021-03-31 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
SI3219726T1 (sl) * 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
BR112018017165A2 (pt) 2016-03-17 2019-01-02 Numab Innovation Ag anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos

Also Published As

Publication number Publication date
TN2018000298A1 (en) 2020-01-16
TWI829444B (zh) 2024-01-11
CN109071650A (zh) 2018-12-21
SI3430043T1 (sl) 2024-01-31
GEP20217307B (en) 2021-10-25
KR20220158877A (ko) 2022-12-01
MD3430043T2 (ro) 2024-02-29
ES2963221T3 (es) 2024-03-26
ZA202108602B (en) 2022-03-30
JP2019512268A (ja) 2019-05-16
KR102470235B1 (ko) 2022-11-24
ZA202108599B (en) 2022-03-30
MA43717A (fr) 2018-11-28
RS64830B1 (sr) 2023-12-29
AU2017235387A1 (en) 2018-09-27
TW201739766A (zh) 2017-11-16
CL2018002649A1 (es) 2018-11-09
EP4275745A2 (en) 2023-11-15
RS61374B1 (sr) 2021-02-26
HRP20231464T1 (hr) 2024-03-01
CA3011784C (en) 2024-04-23
DK3430043T3 (da) 2023-11-27
UY37157A (es) 2017-10-31
TWI784945B (zh) 2022-12-01
MY194041A (en) 2022-11-09
CA3011784A1 (en) 2017-09-21
ZA202108600B (en) 2022-03-30
CR20180448A (es) 2019-01-25
SI3219726T1 (sl) 2021-02-26
AR107917A1 (es) 2018-06-28
ZA202108601B (en) 2022-03-30
EP3219726A1 (en) 2017-09-20
EP3219726B1 (en) 2020-12-02
US20210198353A1 (en) 2021-07-01
PH12018501907A1 (en) 2019-06-17
US20230272059A1 (en) 2023-08-31
IL261031A (en) 2018-10-31
CY1123784T1 (el) 2022-05-27
US11459383B2 (en) 2022-10-04
MA43717B1 (fr) 2023-11-30
JOP20210085A1 (ar) 2023-01-30
EA039760B1 (ru) 2022-03-10
EP4275745A3 (en) 2023-12-20
US20230279091A1 (en) 2023-09-07
WO2017158092A1 (en) 2017-09-21
LT3219726T (lt) 2021-01-25
FI3430043T3 (fi) 2023-11-17
CO2018009783A2 (es) 2018-09-28
EP3430043B1 (en) 2023-08-30
PT3219726T (pt) 2020-12-15
CN109071650B (zh) 2022-05-13
BR112018016667A2 (pt) 2019-02-05
EA201891788A1 (ru) 2019-01-31
JP2022130407A (ja) 2022-09-06
HUE064238T2 (hu) 2024-02-28
LT3430043T (lt) 2023-12-27
EP3430043A1 (en) 2019-01-23
SG11201807062RA (en) 2018-09-27
MX2018011258A (es) 2019-02-13
PT3430043T (pt) 2023-11-23
SA518400027B1 (ar) 2022-03-06
KR20180120149A (ko) 2018-11-05
PL3430043T3 (pl) 2024-03-11
JP7129398B2 (ja) 2022-09-01
DK3219726T3 (da) 2020-12-07
HRP20210123T1 (hr) 2021-03-05
HUE052773T2 (hu) 2021-05-28
ES2836349T3 (es) 2021-06-24
TW202311288A (zh) 2023-03-16
PL3219726T3 (pl) 2021-07-19

Similar Documents

Publication Publication Date Title
JOP20170063B1 (ar) أجسام مضادة لـ TNF- a وشظايا وظيفية منها
PH12018501907A1 (en) Anti-tnfalpha-antibodies and functional fragments thereof
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
WO2015037000A8 (en) Vstm5 polypeptides and uses thereof for treatment of cancer, infectious diseases and immune related diseases
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2015013203A (es) Conjugados de anticuerpo - farmaco.
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
BR112018017276A2 (pt) anticorpos anti-tnf-alfa e fragmentos funcionais dos mesmos
NZ727446A (en) Therapeutic use of p75ntr neurotrophin binding protein
EA201892090A1 (ru) АНТИТЕЛА К ФНО-α И ИХ ФУНКЦИОНАЛЬНЫЕ ФРАГМЕНТЫ
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
AU2016374375A8 (en) Antibody molecules which bind TNF alpha